SYRE
Spyre Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+10/100
Last price
80.50
▼ 12.22 (13.18%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
89.14
Prev close
92.72
Day high
92.08
Day low
79.36
Volume
4.25M
Market cap
$7.06B
P/E (TTM)
—
52W range
16.00 – 110.18
Day trading desk
Gap from prior close
-3.86%
Prior close 92.72
VWAP
80.99
-0.61% from price
Relative volume
7.08×
Unusually busy
Session range
17.28%
79.36 – 93.07
Position in range
8%
Near session low
ATR (14D)
5.49
6.82% of price
Prior day high
95.01
PDH
Prior day low
89.49
PDL
Bid / ask spread
—
Quote not published
Session volume
8.01M
Avg 1.13M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.44%
-7.4%
1M
-9.97%
-11.1%
3M
-16.03%
-20.5%
6M
+56.46%
+38.3%
YTD
+144.54%
+130.3%
1Y
+404.15%
+387.7%
3Y
+553.96%
+471.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SYRE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-4.23M
Net selling
Buy transactions
12
852.58K shares
Sell transactions
19
5.08M shares
Net transactions
+31
Buys less sells
Sell : buy shares
6.0 : 1
Heavily one-sided
Insider-held shares
1.46M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | KING-JONES HEIDY Officer |
SELL | 28.40K | $2.48M | Direct |
| Sep 2, 26 | BURROWS SCOTT L. Chief Financial Officer |
SELL | 25.73K | $2.28M | Direct |
| Sep 2, 26 | KING-JONES HEIDY Officer |
CONVERSION | 28.40K | $411.79K | Direct |
| Sep 1, 26 | TURTLE CAMERON Chief Executive Officer |
SELL | 15.00K | $1.31M | Direct |
| Sep 1, 26 | BURROWS SCOTT L. Chief Financial Officer |
CONVERSION | 7.50K | $108.75K | Direct |
| Aug 7, 26 | ALBERS JEFFREY W Director |
SELL | 23.00K | $2.40M | |
| Aug 7, 26 | ALBERS JEFFREY W Director |
CONVERSION | 5.00K | $51.95K | Direct |
| Aug 3, 26 | TURTLE CAMERON Chief Executive Officer |
SELL | 15.00K | $1.43M | Direct |
| Aug 3, 26 | BURROWS SCOTT L. Chief Financial Officer |
SELL | 7.50K | $716.77K | Direct |
| Aug 3, 26 | BURROWS SCOTT L. Chief Financial Officer |
CONVERSION | 7.50K | $108.75K | Direct |
| Jul 1, 26 | TURTLE CAMERON Chief Executive Officer |
SELL | 15.00K | $1.32M | Direct |
| Jul 1, 26 | BURROWS SCOTT L. Chief Financial Officer |
SELL | 7.50K | $658.04K | Direct |
| Jul 1, 26 | SLOAN SHELDON Officer |
SELL | 8.33K | $730.90K | Direct |
| Jul 1, 26 | BURROWS SCOTT L. Chief Financial Officer |
CONVERSION | 7.50K | $108.75K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALBERS JEFFREY W |
Director | — | Sale |
BURROWS SCOTT L. |
Chief Financial Officer | 79.76K | Sale |
FAIRMOUNT FUNDS MANAGEMENT LLC |
Unknown | — | Sale |
HENDERSON MICHAEL THOMAS |
Director | 68.61K | Sale |
KING-JONES HEIDY |
Officer | 2.85K | Sale |
SLOAN SHELDON |
Officer | 0 | Sale |
TURTLE CAMERON |
Chief Executive Officer | 552.54K | Sale |
Fundamentals
Market cap$7.06B
Enterprise value$6.06B
Revenue (TTM)—
Gross profit$-215.80M
EBITDA—
Net income$-150.21M
EPS (TTM)$-1.66
Free cash flow$-89.05M
Total cash$1.15B
Total debt$0
Book value / share$10.84
Shares outstanding88.17M
Float77.70M
Short % of float14.71%
Dividend yield0.00%
Beta (5Y)3.11
Valuation & profitability ratios
Trailing P/E—
Forward P/E-22.76
PEG ratio—
Price / sales—
Price / book7.39
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-22.98%
Return on assets-19.81%
Debt / equity—
Current ratio18.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $886.00K | $2.33M | — |
| Operating revenue | $0 | $0 | $886.00K | $2.33M | — |
| Research & development | $171.65M | $162.79M | $89.50M | $58.58M | +5.4% |
| Selling, general & admin | $47.91M | $45.78M | $39.95M | $28.53M | +4.7% |
| Total operating expense | $219.56M | $208.57M | $129.45M | $87.11M | +5.3% |
| Operating income | -$219.56M | -$208.57M | -$128.56M | -$84.78M | -5.3% |
| Net interest income | $24.89M | $21.31M | $6.15M | $837.00K | +16.8% |
| Pre-tax income | -$155.22M | -$207.97M | -$338.82M | -$83.95M | +25.4% |
| Tax provision | -$15.00K | $51.00K | -$26.00K | -$136.00K | -129.4% |
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | +25.4% |
| Net income to common | -$155.20M | -$208.02M | -$338.79M | -$83.81M | +25.4% |
| Basic EPS | -1.98 | -3.18 | -13.76 | -24.75 | +37.7% |
| Diluted EPS | -1.98 | -3.18 | -13.76 | -24.75 | +37.7% |
| EBIT | -$219.56M | -$208.57M | -$128.56M | -$84.78M | -5.3% |
| EBITDA | -$219.56M | -$208.57M | -$127.82M | -$82.82M | -5.3% |
| Basic shares | 64.06M | 47.03M | 6.90M | 3.37M | +36.2% |
| Diluted shares | 64.06M | 47.03M | 6.90M | 3.37M | +36.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.72M | $89.42M | $188.89M | $34.86M | — | -4.1% |
| Cash & short-term investments | $756.53M | $603.09M | $339.28M | $55.71M | — | +25.4% |
| Total current assets | $777.78M | $608.47M | $341.53M | $62.26M | — | +27.8% |
| Property, plant & equipment | — | — | $0 | $6.65M | $8.36M | — |
| Total assets | $777.78M | $608.48M | $341.86M | $71.14M | — | +27.8% |
| Total current liabilities | $58.69M | $54.06M | $31.98M | $14.66M | — | +8.6% |
| Total debt | — | — | $0 | $4.63M | $5.06M | — |
| Total liabilities | $62.55M | $90.68M | $157.84M | $20.84M | — | -31.0% |
| Retained earnings | -$1.13B | -$972.43M | -$764.41M | -$425.62M | — | -16.0% |
| Shareholder equity | $715.24M | $517.80M | $184.02M | $50.30M | — | +38.1% |
| Working capital | $719.10M | $554.41M | $309.55M | $47.60M | — | +29.7% |
| Net tangible assets | $715.24M | $517.80M | $184.02M | $50.30M | — | +38.1% |
| Shares issued | 78.19M | 60.26M | 36.06M | 2.61M | — | +29.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | — | +25.4% |
| Depreciation & amortisation | $0 | $0 | $744.00K | $1.96M | — | — |
| Stock-based compensation | $37.61M | $44.83M | $25.68M | $7.11M | — | -16.1% |
| Change in working capital | -$5.93M | -$4.53M | -$5.21M | -$5.50M | — | -30.9% |
| Operating cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | — | -7.5% |
| Capital expenditure | — | — | — | -$38.00K | -$573.00K | — |
| Investing cash flow | -$143.47M | -$353.29M | -$108.39M | $57.01M | — | +59.4% |
| Financing cash flow | $309.02M | $410.91M | $361.08M | $42.68M | — | -24.8% |
| Free cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.18M | — | -7.5% |
| End cash position | $85.72M | $89.42M | $189.22M | $36.42M | — | -4.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $65.50M | $60.41M | $44.64M | $45.25M | $40.15M | +8.4% |
| Selling, general & admin | $16.14M | $15.23M | $12.53M | $11.64M | $11.79M | +5.9% |
| Total operating expense | $81.64M | $75.64M | $57.17M | $56.89M | $51.94M | +7.9% |
| Operating income | -$81.64M | -$75.64M | -$57.17M | -$56.89M | -$51.94M | -7.9% |
| Net interest income | $10.05M | $7.00M | $7.14M | $5.38M | $5.87M | +43.7% |
| Pre-tax income | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | +47.5% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | +47.5% |
| Net income to common | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | +47.5% |
| Basic EPS | -0.43 | -0.74 | -0.70 | -0.18 | -0.60 | +42.5% |
| Diluted EPS | -0.43 | -0.74 | -0.70 | -0.18 | -0.60 | +42.5% |
| EBIT | -$81.64M | -$75.64M | -$57.17M | -$56.89M | -$51.94M | -7.9% |
| EBITDA | -$81.64M | -$75.64M | -$57.17M | -$56.89M | -$51.94M | -7.9% |
| Basic shares | 85.09M | 78.55M | 75.09M | 60.78M | 60.70M | +8.3% |
| Diluted shares | 85.09M | 78.55M | 75.09M | 60.78M | 60.70M | +8.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $162.01M | $97.19M | $85.72M | $64.90M | $81.66M | +66.7% |
| Cash & short-term investments | $1.15B | $741.47M | $756.53M | $486.20M | $526.58M | +54.5% |
| Total current assets | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | +53.5% |
| Total assets | $1.17B | $763.95M | $777.78M | $504.60M | $538.83M | +53.5% |
| Total current liabilities | $63.30M | $85.16M | $58.69M | $46.27M | $83.06M | -25.7% |
| Total liabilities | $71.86M | $93.14M | $62.55M | $49.50M | $83.06M | -22.8% |
| Retained earnings | -$1.23B | -$1.20B | -$1.13B | -$1.07B | -$1.05B | -3.0% |
| Shareholder equity | $1.10B | $670.81M | $715.24M | $455.10M | $455.77M | +64.2% |
| Working capital | $1.11B | $678.79M | $719.10M | $458.33M | $455.77M | +63.5% |
| Net tangible assets | $1.10B | $670.81M | $715.24M | $455.10M | $455.77M | +64.2% |
| Shares issued | 88.06M | 78.84M | 78.19M | 60.47M | 60.37M | +11.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$36.20M | -$69.00M | -$62.53M | -$11.18M | -$36.72M | — | +47.5% |
| Stock-based compensation | $13.51M | $12.81M | $9.81M | $9.57M | $9.38M | — | +5.5% |
| Change in working capital | -$9.01M | $244.00K | -$2.27M | $5.94M | -$9.04M | — | -3,792.6% |
| Operating cash flow | -$69.88M | -$57.37M | -$44.58M | -$37.12M | -$46.56M | — | -21.8% |
| Investing cash flow | -$297.90M | $56.58M | -$247.41M | $25.00M | $79.00M | — | -626.5% |
| Share buybacks | — | — | — | — | $0 | -$117.00K | — |
| Financing cash flow | $432.60M | $12.26M | $312.81M | -$4.64M | $731.00K | — | +3,430.0% |
| Free cash flow | -$69.88M | -$57.37M | -$44.58M | -$37.12M | -$46.56M | — | -21.8% |
| End cash position | $162.01M | $97.19M | $85.72M | $64.90M | $81.66M | — | +66.7% |
Options analytics
Put / call volume
0.47
Call-heavy session
Put / call open interest
8.13
Positioning, not flow
Max pain
95.00
+18.6% from spot
ATM implied vol
72.8%
Nearest strike to spot
Skew (10% OTM)
+45.7%
Puts bid over calls
Call volume
251
Contracts, this expiry
Put volume
119
Contracts, this expiry
Heaviest call OI
90.00
34 contracts
Heaviest put OI
85.00
215 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.75 | -0.36 | +51.8% |
| Mar 2026 | -0.65 | -0.74 | -13.1% |
| Dec 2025 | -0.80 | -0.74 | +7.2% |
| Sep 2025 | -0.74 | -0.15 | +79.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.83 | 13 | $0 | 0.0% |
| Next quarter | -0.87 | 13 | $0 | 0.0% |
| Current year | -2.87 | 13 | $0 | 0.0% |
| Next year | -3.52 | 13 | $0 | 0.0% |
Analyst targets & ownership
Mean target$120.21
High target$130.00
Low target$97.00
Implied upside49.33%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy1 / 15
Hold1
Sell / Strong sell0 / 0
Held by insiders1.66%
Held by institutions111.62%
Institutions holding381
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
87.64
-8.15% from price
SMA 20
89.13
-10.12% from price
SMA 50
95.39
-16.02% from price
SMA 100
90.42
-10.97% from price
SMA 200
68.16
+17.53% from price
EMA 12
88.41
-8.94% from price
EMA 26
90.32
-10.87% from price
EMA 50
91.51
-12.03% from price
RSI (14)
34.3
Neutral
MACD (12,26,9)
-1.91
Hist 0.06
ATR (14)
5.49
6.86% of price
Realised vol 30D
65.0%
Annualised
Bollinger upper
95.56
20, 2σ
Bollinger lower
82.70
20, 2σ
50 / 200 cross
Golden
95.39 vs 68.16
Trend bias
Above 200
+17.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.80
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
65.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.5%
Peak to trough
Max drawdown 5Y
-98.7%
Peak to trough
ATR 14
5.49
6.86% of price
Beta (reported)
3.11
5Y monthly, from filing
Short interest
Shares short
12.13M
Prior 11.76M
Change vs prior
+3.2%
Shorts adding
% of float
14.71%
Elevated
% of shares out
13.76%
Against total outstanding
Days to cover
10.4
Crowded exit
Float
77.70M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | JP Morgan | INITIATED | — | Overweight |
| Oct 1, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 8, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 26, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| Aug 26, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 28, 26 | Wolfe Research | DOWNGRADE | Outperform | Peer Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:25
Split dateSep 8, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-25
Corporate Changes & Voting Matters
8-K · 2026-08-04
Offering Registrations
S-3ASR · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-05
Headlines
Update: Spyre Shares Fall After Pricing $350 Million Stock Offering
MT Newswires · 7h ago
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
TIKR · 9h ago
Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell
MT Newswires · 18h ago
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
GlobeNewswire · 1d ago
Spyre Therapeutics stock falls on public offering launch
Investing.com · 1d ago
Spyre Therapeutics Commences Public Offering of Common Stock
MT Newswires · 1d ago
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
GlobeNewswire · 1d ago
Spyre Therapeutics Insider Sold Shares Worth $2,261,831, According to a Recent SEC Filing
MT Newswires · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.